Tag : PAOG

CCT Impact

PAOG Partners With PURA, ALKM and USMJ To Launch CBD Nutraceutical Product Line

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today released a preview of the company’s plan to launch a CBD Nutraceuticals line of products.  PAOG’s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of......
CCT Impact

PAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership Highlights

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today highlighted that the upcoming CBD Nutraceutical Sales Rollout Presentation scheduled for tomorrow, Friday, May 7, 2021, will feature the roles Alkame Holdings, Inc. (USOTC: ALKM) and North American Cannabis Holdings, Inc. (USOTC: USMJ) play in the CBD Nutraceutical Rollout. Last year, PAOG acquired RespRx from......
CCT Impact

PAOG Announces Negotiations To Acquire Partnership Interest In Patented Cannabis Extraction Technology

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today released a management update on the company’s ongoing CBD Pharmaceutical Development Program. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method –......
CCT Impact

PAOG To Publish Latest CBD Pharmaceutical Developments Tomorrow, Tuesday April 13, 2021

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today confirmed a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive......
CCT Impact

PAOG U.S. Patent Backed CBD Pharmaceutical Development Remains On Track

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive......
CCT Impact

PAOG CBD RELAX-RX Nutraceutical Plans To Co-Pack With ALKM And Market With USMJ Detailed In Update Scheduled Next Week

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today announced an update scheduled one week from today, for Tuesday, March 16, 2021 to publish details on the company’s CBD RELAX-RX nutraceutical development plans including intended co-packing with Alkame Holdings, Inc. (USOTC: ALKM) and marketing with North American Cannabis Holdings, Inc. (USOTC: USMJ). CBD RELAX-RX targets......
CCT Impact

PAOG Expects To Add CBD Nutraceuticals Revenue This Year

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today highlighted the company’s anticipated revenue expected this year from its CBD nutraceutical expansion.  Earlier this week, the company published an online, multimedia presentation detailing the company’s CBD nutraceutical development expansion plans.  The presentation includes details on PAOG’s strategic engagements with Puration, Inc. (USOTC: PURA),......
CCT Impact

PAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today revealed plans to expand its nutraceutical product reach. The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).......
CCT Impact

PAOG Takes Next Step To Produce Cannabis Nutraceuticals

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today announced moving forward with its initiative to produce cannabis nutraceuticals. PAOG recently engaged with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated......
CCT Impact

PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals

CCT IMPACT Agent
PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year.  The strategic outlook is included in its entirety below: PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook PAOG is a longtime participant in the cannabis sector......